BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 11, 2021 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2020.

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Pablo Cagnoni, M.D., to its board of directors. Dr. Cagnoni brings to Synthekine extensive leadership experience in the biotech industry and a successful track record of oncology drug development.

Aytu BioScience, Inc. (NASDAQ:AYTU) , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET.

Hologic, Inc. (Nasdaq: HOLX) announced today the on-line publication of its 2020 sustainability report, “The Power of Purpose.”

Researchers and clinical experts at Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, were awarded Department of Defense funds to continue their work into convalescent plasma for treatment of COVID-19 patients.

The Food Allergy Science Initiative announced the beginning of a new era as a separate, independent organization dedicated to discovering the root causes of food allergies through rigorous scientific research and deploying new therapies to treat and, ultimately, cure them.

V-Bio Ventures (V-Bio) announces today the first closing of V-Bio Fund 2 with capital commitments of EUR 78 million (USD 95 million).

Dr. Auerbach will further strengthen OCON’s efforts in expanding and developing ground-breaking intrauterine solutions to better women’s health for world-wide markets including the USA

proteanTecs, a leading provider of health and performance monitoring solutions for advanced electronics, announced today the appointment of former Optimal+ (acquired by National Instruments) executive, Uzi Baruch, as chief strategy officer.

The primary purpose of the agreement is for Cukierman to assist BioHarvest in forming strategic and commercial partnerships with relevant pharmaceutical companies.